$CERS gap & now FDA Pr. $6.16 FDA Approves INTER
Post# of 63700
Posted On: 12/18/2014 8:17:53 PM
$CERS gap & now FDA Pr. $6.16
FDA Approves INTERCEPT Blood System for Platelets 7:45 PM
100% Buy
Website
Shares Outstanding: 78.27M
Float: 57.90M
% Held by Insiders: 1.54%
% Held by Institutions: 63.50%
Shares Short (as of Nov 28, 2014): 12.12M
Short Ratio (as of Nov 28, 2014): 11.60
Short % of Float (as of Nov 28, 2014): 19.20%
Shares Short (prior month): 12.05M
10-Q 11/7/13
Summary
Recent Trades
Headlines
Thursday, December 18, 2014
FDA Approves INTERCEPT Blood System for PlateletsBusiness Wire (Thu 7:20PM EST)
Wednesday, December 17, 2014
Equity markets surge...so many stories – where to begin?Yahoo Finance Blogs (Wed, Dec 17)
Cerus jumps on FDA OK for plasma treatmentat MarketWatch (Wed, Dec 17)
Now it’s the Fed’s turn to pour grease on the market fireat MarketWatch (Wed, Dec 17)
Tuesday, December 16, 2014
5:36 pm Cerus confirms FDA approval of INTERCEPT Blood System for plasmaBriefing.com (Tue, Dec 16)
FDA Approves INTERCEPT Blood System for PlasmaBusiness Wire (Tue, Dec 16)
Friday, November 21, 2014
FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent PlasmaBusiness Wire (Fri, Nov 21)
Saturday, November 15, 2014
CERUS CORP FinancialsEDGAR Online Financials (Sat, Nov 15)
Sunday, November 9, 2014
10-Q for Cerus Corp.Company Spotlight (Sun, Nov 9)
Friday, November 7, 2014
CERUS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri, Nov 7)
Wednesday, November 5, 2014
Cerus (CERS) Stock: Weak On High Volume Todayat TheStreet (Wed, Nov 5)
Tuesday, November 4, 2014
Cerus posts 3Q lossAP (Tue, Nov 4)
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Tue, Nov 4)
Cerus Corporation Reports Third Quarter 2014 ResultsBusiness Wire (Tue, Nov 4)
Wednesday, October 29, 2014
Cerus Announces Agreement With Kawasumi Laboratories for the Development of INTERCEPT Platelets Kits in JapanBusiness Wire (Wed, Oct 29)
Thursday, October 23, 2014
American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety RisksBusiness Wire (Thu, Oct 23)
Wednesday, October 22, 2014
Cerus to Release Third Quarter 2014 Results on November 4, 2014Business Wire (Wed, Oct 22)
Tuesday, October 21, 2014
Strength Seen in Cerus (CERS): Stock Gains 6.2%Zacks (Tue, Oct 21)
Monday, October 20, 2014
Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent PlasmaBusiness Wire (Mon, Oct 20)
Tuesday, October 7, 2014
U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety RisksBusiness Wire (Tue, Oct 7)
FDA Approves INTERCEPT Blood System for Platelets 7:45 PM
100% Buy
Website
Shares Outstanding: 78.27M
Float: 57.90M
% Held by Insiders: 1.54%
% Held by Institutions: 63.50%
Shares Short (as of Nov 28, 2014): 12.12M
Short Ratio (as of Nov 28, 2014): 11.60
Short % of Float (as of Nov 28, 2014): 19.20%
Shares Short (prior month): 12.05M
10-Q 11/7/13
Summary
Recent Trades
Headlines
Thursday, December 18, 2014
FDA Approves INTERCEPT Blood System for PlateletsBusiness Wire (Thu 7:20PM EST)
Wednesday, December 17, 2014
Equity markets surge...so many stories – where to begin?Yahoo Finance Blogs (Wed, Dec 17)
Cerus jumps on FDA OK for plasma treatmentat MarketWatch (Wed, Dec 17)
Now it’s the Fed’s turn to pour grease on the market fireat MarketWatch (Wed, Dec 17)
Tuesday, December 16, 2014
5:36 pm Cerus confirms FDA approval of INTERCEPT Blood System for plasmaBriefing.com (Tue, Dec 16)
FDA Approves INTERCEPT Blood System for PlasmaBusiness Wire (Tue, Dec 16)
Friday, November 21, 2014
FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent PlasmaBusiness Wire (Fri, Nov 21)
Saturday, November 15, 2014
CERUS CORP FinancialsEDGAR Online Financials (Sat, Nov 15)
Sunday, November 9, 2014
10-Q for Cerus Corp.Company Spotlight (Sun, Nov 9)
Friday, November 7, 2014
CERUS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri, Nov 7)
Wednesday, November 5, 2014
Cerus (CERS) Stock: Weak On High Volume Todayat TheStreet (Wed, Nov 5)
Tuesday, November 4, 2014
Cerus posts 3Q lossAP (Tue, Nov 4)
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Tue, Nov 4)
Cerus Corporation Reports Third Quarter 2014 ResultsBusiness Wire (Tue, Nov 4)
Wednesday, October 29, 2014
Cerus Announces Agreement With Kawasumi Laboratories for the Development of INTERCEPT Platelets Kits in JapanBusiness Wire (Wed, Oct 29)
Thursday, October 23, 2014
American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety RisksBusiness Wire (Thu, Oct 23)
Wednesday, October 22, 2014
Cerus to Release Third Quarter 2014 Results on November 4, 2014Business Wire (Wed, Oct 22)
Tuesday, October 21, 2014
Strength Seen in Cerus (CERS): Stock Gains 6.2%Zacks (Tue, Oct 21)
Monday, October 20, 2014
Cerus Submits Compassionate Use IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent PlasmaBusiness Wire (Mon, Oct 20)
Tuesday, October 7, 2014
U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety RisksBusiness Wire (Tue, Oct 7)
(0)
(0)Scroll down for more posts ▼